Baksheev L, Fuller P J
Prince Henry's Institute of Medical Research and Monash University Department of Medicine, Monash Medical Centre, PO Box 5152, Clayton, Victoria 3168, Australia.
Trends Endocrinol Metab. 2000 Dec;11(10):401-5. doi: 10.1016/s1043-2760(00)00307-6.
The small bowel has a remarkable ability to adapt after injury, inflammation or resection. It has long been suggested that humoral factors, particularly enteroglucagon, epidermal growth factor, neurotensin and growth hormone/insulin-like growth factor I, might stimulate bowel growth. Of particular interest is the recent finding that glucagon-like peptide 2 (GLP-2), a product of the gene encoding proglucagon, exerts a trophic effect on the intestinal epithelium via a specific G-protein-coupled receptor. GLP-2 and/or these other trophic peptides might prove to have a role in the treatment of bowel diseases associated with structural or functional loss of the small bowel.
小肠在损伤、炎症或切除术后具有显著的适应能力。长期以来，人们一直认为体液因子，特别是肠高血糖素、表皮生长因子、神经降压素和生长激素/胰岛素样生长因子I，可能刺激肠道生长。特别令人感兴趣的是最近的一项发现，即胰高血糖素样肽2（GLP-2），一种由胰高血糖素原编码基因产生的产物，通过一种特定的G蛋白偶联受体对肠上皮发挥营养作用。GLP-2和/或这些其他营养肽可能在治疗与小肠结构或功能丧失相关的肠道疾病中发挥作用。
